slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 74,431-74,460
Pages 3,225
Rows per page 30
Component
74,431-74,460 of 96,741
94
The slide uses a Q&A transcript format to corroborate previous claims about drug instability and poor blood-brain barrier penetration.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
95
The slide uses expert testimony to establish a precedent of failure in the H3 receptor space, specifically contrasting J&J's robust trials with Bioprojet's pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
97
The slide uses highlighted text to emphasize key claims about compound quality and pharmacokinetic challenges.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
98
The slide uses direct quotes from a J&J scientist to undermine the credibility of Bioprojet's research capabilities.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
99
The slide uses a combination of summary bullet points and direct quotes from a consultation call to discredit the competitor's scientific rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
100
The slide uses highlighted text to emphasize key quotes from expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
102
Uses Q&A format to frame expert opinion as a critique of Bioprojet's claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
109
The slide uses a table to contrast initial high-dose trials with subsequent lower-dose trials to imply company knowledge of toxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
110
The slide uses a 'before-after' or 'comparison' structure to highlight the exclusion criteria in two different trial papers.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
111
The slide uses a 'villain critique' style to highlight a lack of transparency in clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
112
The slide uses a 'fraud-exposure' narrative to highlight missing safety data in regulatory filings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
113
The slide uses a critical tone to challenge the integrity of the reported clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
114
The slide uses a critical tone to highlight potential data manipulation or poor reporting practices in a clinical trial publication.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
115
The slide uses a red underline to emphasize the specific clinical findings in the excerpt.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
117
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
118
The slide uses a 'black box' argument to challenge the validity of the sponsor's pharmacokinetic model.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
119
The slide uses direct quotes from the EMA's CHMP assessment report to highlight regulatory discrepancies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
120
The slide uses a combination of narrative argument and a direct quote from a consultant to build a case against the company's transparency.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
121
The slide presents a direct quote from a PK expert to undermine the validity of the company's safety assertions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
124
The slide uses a specific FDA review document (NDA 211150) to challenge official plasma level claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
126
The slide uses a table to expose data inconsistencies and safety risks, framing the variability as a 'red flag' regarding the drug's safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
127
The slide uses a '>' prefix, suggesting it is a direct, provocative assertion or a 'villain' critique.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
128
The slide uses a direct quote from an FDA clinical review to contradict the company's safety claims, supported by a table of clinical data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
129
The slide highlights the safety margin between the recommended dose (40mg) and the doses where QTc prolongation was observed (120-240mg), while noting specific patient populations at higher risk.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
133
The slide uses a red box to highlight the specific column in the table containing the erroneous data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
134
The slide documents the source data used by a consultant to derive a linear regression model for QTc vs. plasma levels.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
136
Includes a linear regression equation Y=14.62*X+53.34 and a scatter plot with error bars.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
137
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
139
The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
141
The slide uses direct citations from peer-reviewed papers to validate the consultant's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit